8-K 1 a06-24486_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2006

Tapestry Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

 

0-24320

 

84-1187753

(State of
incorporation)

 

(Commission
File Number)

 

IRS Employer
Identification No.)

 

4840 Pearl East Circle, Suite 300W
Boulder, Colorado 80301

(Address of principal executive offices and zip code)

(303) 516-8500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o               Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o               Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o               Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o               Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



INFORMATION TO BE INCLUDED IN THE REPORT

Item 1.02  Termination of a Material Definitive Agreement.

On November 16, 2006, Tapestry Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into a Note Purchase Agreement with TL Ventures V L. P. and TL Ventures V Interfund L. P. (collectively, “TL Ventures”).  In accordance with the Note Purchase Agreement, on November 17, 2006, the Company repurchased two non-interest bearing promissory notes issued by the Company to TL Ventures in February 2005 (the “Notes”). The Notes had an outstanding principal balance of $3.02 million.  The Notes were repurchased for an aggregate payment to TL Ventures of $2.69 million in cash.  Repurchase of the Notes did not have a material impact on the Company’s financial results.

2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 21, 2006

TAPESTRY PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ Kai Larson

 

 

Name:

Kai Larson

 

Title:

Vice President, General Counsel

 

3